Graphical representation of how HBV/HCV-induced CTNNB1 mutations drive HCC progression. HBV/HCV infection can introduce somatic mutations in exon 3 of CTNNB1, impairing the phosphorylation site and subsequently preventing the degradation of β-catenin, allowing aberrant activation of transcription factors, and driving HCC progression. hepatitis B virus; HCV, hepatitis C virus; TCF/LEF, T-cell factor/lymphoid enhancer factor; HCC, hepatocellular carcinoma.

 
 
  Part of: Fajardo LE, Macalalad MA, Odchimar NM, de Guzman JC, Orosco F (2024) Computational design and validation of siRNA molecules to silence oncogenic CTNNB1 mRNA as a potential therapeutic strategy against hepatitis B/C virus-associated hepatocellular carcinoma. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e127981